Technical Advantage

Technological Advantages

Technical Advantage

The First Affiliated Hospital of Guangzhou Medical University


Guangzhou Medical University Affiliated First Hospital is a large-scale Grade III Class A hospital integrating medical care, education, research, health services, rehabilitation, and pre-hospital emergency care. It also serves as the headquarters for the Guangzhou Institute of Respiratory Diseases, the Guangzhou Institute of Orthopedics, the Guangzhou Institute of Urology, and the Guangzhou Medical University Institute of Integrated Traditional Chinese and Western Medicine—and was among the first batch of hospitals designated by the national government. One of 13 National Clinical Medical Research Centers.

In 2020, Jiuzhitang Maker signed a Research Collaboration Agreement with the First Affiliated Hospital of Guangzhou Medical University. Together, the two parties are jointly conducting research to evaluate the effectiveness of bone marrow mesenchymal stem cell therapy for lung diseases. In June 2023, Jiuzhitang Maker received approval (Acceptance No.: CXSL2300202) for the clinical trial of its second stem-cell-based new drug, with the indication targeting autoimmune alveolar proteinosis (aPAP). On November 1, 2023, this groundbreaking clinical trial officially kicked off, as Jiuzhitang Maker collaborates with the First Affiliated Hospital of Guangzhou Medical University to carry out a Phase IIa clinical study investigating hBMMSC treatment for patients with autoimmune alveolar proteinosis (aPAP).